by David Cassak and Stephen Levin
Uneasy lies the head that wears the crown, said Shakespeare. In business, market leadership is an enviable position—until things start...
Six months after a significant management change, Zimmer officials claim the orthopedics leader is back on track. But in today's environment, can even a successful orthopedics company please its drug-company parent?
by David Cassak and Stephen Levin
Uneasy lies the head that wears the crown, said Shakespeare. In business, market leadership is an enviable position—until things start...
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.